The question
Is it possible to reliablyand safelyextend a dogs life?
The declaration was an important part of the companys development of the drug.
But the company isnt stopping there.
Boo the dog, the first patient of Loyal’s STAY trial testing out their LOY-002 drug.© John Poisson/Loyal
The team has developed a daily pill version of LOY-001 for large dogs, called LOY-003.
Thats a concern that Loyal is well aware of and will be measuring in its ongoing research.
Loyal was founded in 2019 by CEO Celine Halioua, herself a long-time animal owner.
© Vicky Leta/Gizmodo
Its three drugs would be its first successful products to reach the market, if approved.
In February 2024, the companydosed its first subjectof the STAY trial, a 11-year-old dog named Boo.
Theres been tremendous enthusiasm.
Veterinarians are eager to have another tool in their toolbox, McKenzie said.
So it absolutely is a community process for sure.
Click here to see all of thewinners of the 2024 Gizmodo Science Fair.
News from the future, delivered to your present.
